Poxel Owners | StatInvestor

Health Care & Life Sciences » Biotechnology | Poxel

Poxel S.A. | Ownership

Companies that own Poxel S.A.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Federated Global Investment Management Corp.

902,220

3.67%

0.05%

06/29/2018

JPMorgan Asset Management (UK) Ltd.

789,796

3.22%

-331,988

0.01%

04/27/2018

Bellevue Asset Management AG

121,120

0.49%

-5,500

0.01%

12/29/2017

Etoile Gestion SA

88,020

0.36%

0.02%

01/31/2018

Tocqueville Finance SA

80,369

0.33%

0.04%

07/31/2018

CPR Asset Management SA

72,718

0.3%

0.01%

01/31/2018

La Banque Postale Asset Management SA

61,029

0.25%

06/29/2018

Amundi Asset Management SA (Investment Management)

55,005

0.22%

01/31/2018

Gestys SA

25,000

0.1%

5,000

2.98%

03/23/2018

Lyxor International Asset Management SAS

14,017

0.06%

09/05/2018

About Poxel

View Profile

Address	259/261, avenue Jean Jaurès Lyon Rhone-Alpes 69007 France
Employees	-
Website	http://www.poxel.com
Updated	07/08/2019
Poxel SA is a pharmaceutical company, which engages in development of molecules for the potential treatment of type 2 diabetes. Its products include Imeglimin-US/EU, Imeglimin-Japan/Asia, and PXL770. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.